RhumbLine Advisers’s Trinity Biotech TRIB Stock Holding History

RhumbLine Advisers’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.64K	Buy	312 +127	+69%	+$2.35K	﹤0.01%	3984
2026 Q1	$3K	Sell	185 -27	-13%	-$596	﹤0.01%	3909
2025 Q4	$5.04K	Buy	212 +206	+3,433%	+$6.07K	﹤0.01%	3921
2025 Q3	$186	Sell	6 -36	-86%	-$1.14K	﹤0.01%	4080
2025 Q2	$838	Sell	42 -2	-5%	-$40	﹤0.01%	4049
2025 Q1	$746	Sell	44 -16	-27%	-$379	﹤0.01%	4041
2024 Q4	$1.59K	Hold	60	–	–	﹤0.01%	4052
2024 Q3	$1.99K	Buy	60 +48	+400%	+$3.24K	﹤0.01%	4060
2024 Q2	$769	Hold	12	–	–	﹤0.01%	4262
2024 Q1	$761	Hold	12	–	–	﹤0.01%	4168
2023 Q4	$797	Hold	12	–	–	﹤0.01%	4168
2023 Q3	$1.35K	Hold	12	–	–	﹤0.01%	4157
2023 Q2	$1.79K	Buy	+12	New	+$1.74K	﹤0.01%	4232

Other funds holding TRIB

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

MAWA

Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

BCM

Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers's TRIB Position: Q2 2026 in Review

RhumbLine Advisers increased its Trinity Biotech (TRIB) stake by 69% in Q2 2026, buying an estimated $2.35K and bringing the position to 312 shares worth $3.64K. The position accounts for ﹤0.01% of the portfolio, ranked #3984.

RhumbLine Advisers first reported a position in TRIB in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.04K in Q4 2025. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.

RhumbLine Advisers held 312 shares of Trinity Biotech worth $3.64K as of Q2 2026.
RhumbLine Advisers bought 127 Trinity Biotech shares in Q2 2026, an estimated $2.35K.
Trinity Biotech made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3984 holding.
RhumbLine Advisers first reported a position in Trinity Biotech in Q2 2023 and has held it in 13 quarters since.
RhumbLine Advisers's Trinity Biotech position peaked at $5.04K in Q4 2025.
19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.